J Am Coll Cardiol. 2017 Feb 21;69(7):871-898. doi: 10.1016/j.jacc.2016.11.024. Epub 2017 Jan 9.
Periprocedural management of anticoagulation is a common clinical conundrum that involves a multidisciplinary team, cuts across many specialties, and varies greatly between institutions in the way it is practiced. Nowhere is this more evident than in the management of patients with nonvalvular atrial fibrillation. Although they have been found to improve patient outcomes, standardized evidence-based protocols are infrequently in place. The frequency of anticoagulant interruption in preparation for a procedure is high, with an estimated 250,000 patients undergoing temporary interruption annually in North America alone. Knowledge about risk of bleeding and short-term thrombotic risk resides in many specialties, further complicating the issue. Our goal in creating this pathway is to help guide clinicians in the complex decision making in this area. In this document, we aim to: 1) validate the appropriateness of the decision to chronically anticoagulate; 2) guide clinicians in the decision of whether to interrupt anticoagulation; 3) provide direction on how to interrupt anticoagulation with specific guidance for vitamin K antagonists and direct-acting oral anticoagulants; 4) evaluate whether to bridge with a parenteral agent periprocedurally; 5) offer advice on how to bridge; and 6) outline the process of restarting anticoagulation post-procedure.
抗凝治疗的围手术期管理是一个常见的临床难题,涉及多学科团队,跨越多个专业,并且不同机构的实践方式也存在很大差异。在非瓣膜性心房颤动患者的管理中,这一点最为明显。尽管已经发现这些治疗方法可以改善患者的预后,但标准化的循证方案却很少实施。为了准备手术而中断抗凝治疗的频率很高,仅在北美每年就估计有 25 万名患者需要临时中断抗凝治疗。关于出血风险和短期血栓形成风险的知识存在于许多专业领域,这进一步使问题复杂化。我们创建这条路径的目标是帮助指导临床医生在这一领域进行复杂的决策。在本文件中,我们旨在:1)验证长期抗凝治疗决策的合理性;2)指导临床医生决定是否中断抗凝治疗;3)提供关于如何中断抗凝治疗的指导,包括维生素 K 拮抗剂和直接口服抗凝剂的具体指导;4)评估是否需要在围手术期使用静脉内药物进行桥接;5)提供桥接的建议;6)概述术后重新开始抗凝治疗的过程。